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ABSTRACT
In the present era of ever-increasing antibiotic
resistance and increasingly complex and
immunosuppressed patient populations,
physicians and scientists are seeking novel
approaches to battle difficult infectious disease
conditions. Development of a serious infection
implies a failure of innate immune capabilities
in the patient, and one may consider whether
pharmacological strategies exist to correct and
enhance innate immune cell function.
Hypoxia-inducible factor-1 (HIF-1), the central
regulator of the cellular response to hypoxic
stress, has recently been recognized to control
the activation state and key microbicidal
functions of immune cells. HIF-1 boosting
drugs are in clinical development for anemia
and other indications, and could be
repositioned as infectious disease therapeutics.
With equal attention to opportunities and
complexities, we review our current
understanding of HIF-1 regulation of microbial
host–pathogen interactions with an eye toward
future drug development.
Keywords: Bacteria; Dendritic cells; Hypoxia-
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INTRODUCTION
The golden age of antibiotics may be nearing its
end, as more and more pathogens acquire
resistance to an ever-widening range of
antibiotics. New ways to prevent and treat
infectious diseases are urgently needed. One
possible solution is to focus on the other side of
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the host–pathogen equation—not killing the
invaders, but strengthening the defenses. Just as
vaccines harness the power of the adaptive
immune system to prevent infectious disease,
treatments that activate the innate immune
system could potentially help to cure acute
infections. Hypoxia-inducible factor (HIF)—a
transcriptional regulator that controls the key
aspects of the immune response—is a promising
target for such immune-boosting treatments. HIF
regulates theenergy generation and productionof
multiple microbicidal effectors of phagocytic cells
including neutrophils and macrophages, and
established pharmacological strategies exist to
increase cellular HIF levels. But one must proceed
prudently, since a growing body of research
reveals that HIF plays multiple roles in immune
regulation, with differing effects in different cell
types. Strategies to modulate HIF levels for
infectious disease therapy must take these
complexities into consideration.
HIF BIOLOGY AND REGULATION
Hypoxia-inducible factor is a basic helix–loop–
helix transcription factor [1] first identified for
its role in erythropoietin regulation [2], but later
discovered to also regulate genes involved in
glycolysis, angiogenesis, cell differentiation,
apoptosis, and other cellular pathways [3]. HIF
is a heterodimer composed of a HIF-a subunit
and HIF-1b subunit. Hif-a is actually a family of
three genes: Hif1a, Hif2a, and Hif3a. HIF-3a is
distantly related to HIF-1a and HIF-2a and little
is known about its function, although it may
inhibit the activity of HIF-1a and HIF-2a [4].
The HIF-1a and HIF-2a subunits are closely
related, sharing 48% overall amino acid identity
[5]. The two subunits are very similar in their
DNA binding and dimerization domains but
differ in their transactivation domains,
implying that they may regulate unique sets of
target genes [5]. Whereas HIF-1a is ubiquitously
expressed, HIF-2a is most abundantly expressed
in vascular endothelial cells during embryonic
development and in endothelial, lung, heart [6],
and bone marrow cells [7] in the adult. HIF-2a
levels are closely correlated with vascular
endothelial growth factor (VEGF) mRNA
expression [6] and are frequently elevated in
solid tumors [7], suggesting that its most
important functions may lie in vascularization
[6]. Since only a small fraction of published
research focuses specifically on HIF-2a or HIF-
3a, this review will be restricted primarily to
HIF-1a.
In the presence of oxygen and the absence of
inflammatory stimuli, the level of HIF-a is kept
low by two mechanisms. In one, HIF-a is
hydroxylated by prolyl hydroxylases [8]. The
hydroxylated HIF-a is recognized by the
ubiquitin ligase von Hippel–Lindau factor
(vHL), which ubiquitinates HIF-a, targeting it
for destruction via the proteasome [9]. In the
second mechanism, factor inhibiting HIF (FIH)
hydroxylates HIF-a, blocking its ability to
associate with p300-CREB binding protein
(CREB-BP), which in turn inhibits the ability
of the HIF complex to bind DNA and promote
transcription [10]. When oxygen tension is low,
neither hydroxylation event occurs, HIF-a and
HIF-1b dimerize, combine with CREB-BP and
bind to hypoxia-response elements (HRE) in the
promoter regions of over a hundred target genes
[3].
The NF-jB pathway appears to be crucial for
the induction of HIF in response to hypoxia
[11]. The human HIF-1a promoter contains a
canonical NF-jB binding site -197/-188 base
pairs upstream of the transcriptional start site,
the mutation of which leads to a loss of hypoxic
HIF-1a upregulation [11]. There is evidence that
NF-jB family members bind to the HIF-1a
promoter [12], and the endogenous inhibitor
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of NF-jB, IjBa, derepresses HIF-1 by
sequestering FIH [13]. Basal NF-jB activity is
required for HIF-1a protein accumulation under
hypoxia in cultured cells and in the liver and
brain of hypoxic animals [11]. IKK-b deficiency
results in defective induction of HIF-1a target
genes including VEGF. IKK-b is also essential for
HIF-1a accumulation in macrophages during
the response to bacterial infection. Hence, IKK-b
is an important physiological contributor to the
hypoxic response, linking it to innate immunity
and inflammation [11].
Though HIF was first identified and named
for its role in hypoxia, later work showed that a
variety of molecular signals of infection and
inflammation may increase HIF activity even
under normoxic conditions. Growth hormones
such as insulin-like growth factor [14],
cytokines such as interleukin-1b (IL-1b) [15]
and viral proteins [16] all activate HIF. This
regulation can occur at the transcriptional,
translational, or post-translational levels. For
example, lipopolysaccharide (LPS) induces
Hif1a mRNA expression in a toll-like receptor
4 (TLR4)-dependent manner that involves
members of the NF-jB, mitogen-activated
protein kinase (MAPK), and extracellular
signal-regulated kinase (ERK) pathways [17–
19]. TLR7/8 ligation also leads to Hif1a
transcript accumulation [20] and to protein
stabilization in macrophages [20, 21].
Cytokines, on the other hand, often increase
HIF activity by post-translational mechanisms.
TGF-b1 enhances HIF-1a protein stability by
inhibiting the expression of prolyl hydroxylase
2 (PHD2), which hydroxylates HIF and targets it
for proteolytic destruction [22]. Tumor necrosis
factor-a (TNF-a) [23] and IL-1b [15, 24] induce
HIF-1a protein stabilization in an NF-jB-
dependent mechanism without affecting its
mRNA level.
HIF AS A REGULATOR OF IMMUNE
FUNCTION
Why should a ubiquitous transcription factor be
induced by both hypoxia and molecular signals
of infection? Tissue foci of inflammation
represent hypoxic microenvironments, with
oxygen tensions measured under 1% [25].
Hypoxia reflects increased metabolic demands
due to a high density of inflammatory cells and
microorganisms, and limited perfusion because
of thrombosis, damage to the vasculature, or
compression of blood vessels due to interstitial
hypertension. Immune cells, therefore, need to
be able to carry out their functions under
conditions of reduced oxygen tension, a
situation made even more challenging since
many leading bacterial pathogens proliferate
readily even in anaerobic microenvironments.
Since infection and hypoxia are so often
encountered together, it perhaps stands to
reason that HIF would be induced not only by
hypoxia but also in response to a broad range of
infections: viral, bacterial, protozoan, and
fungal [26, 27].
HIF IN REGULATION OF INNATE
IMMUNITY
Hypoxia-inducible factor has been proposed as
a master regulator of innate immunity [28]. HIF
expression in epithelial cells can control the
release of chemoattractants that recruit
neutrophils to the site of infection or
inflammation. Dendritic cells (DCs) exposed to
hypoxia upregulate genes coding for proteins
chemotactic for neutrophils such as chemokine
(C-X-C motif) ligand (CXCL)2, CXCL3, CXCL5,
and CXCL8 [29]. HIF induces b2 integrin
expression in neutrophils [30], and Cdc42 and
Rac1 expression in macrophages [31],
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enhancing migration of both cell types to the
site of infection. Hypoxia also increases CXC
chemokine receptor (CXCR)4 [32] and inhibits
CC chemokine receptor (CCR)5 [33] expression
in macrophages in a HIF-dependent manner,
which increases retention of macrophages at
the site of infection.
Not only are more immune cells recruited
and retained, but those cells live longer. HIF
extends the functional neutrophil lifespan by
inhibiting apoptotic pathways in an NF-jB-
dependent manner [34, 35]. People with
mutations in vHL—and therefore
constitutively elevated HIF levels—have
neutrophils with longer lifespans. Hypoxia
also promotes survival of monocytes and
macrophages [36]. HIF transcriptional
regulation also supports other phenotypes
related to immune cell activation. Hypoxia
leads to TLR-2, TLR-4, and TLR-6 upregulation
in a HIF-dependent manner [37, 38], enhancing
the detection of pathogen-associated molecular
patterns. Hypoxic myeloid cells from mice
exhibit increased phagocytosis [39], and those
from humans who have mutations in vHL have
increased phagocytic capacity as well [40].
In an in vivo model of innate infection, mice
lacking HIF-1a in myeloid cells had diminished
capacity to fight off a skin infection with the
pathogen group A Streptococcus (GAS) [41]. Hif1a
knockdown by siRNA also led to more severe
corneal disease in mice infected intraocularly
with Pseudomonas aeruginosa, and this effect was
due to impaired neutrophil function [42].
Conversely, mice in which HIF was elevated
by drug treatment were better able to control
skin infection by methicillin-resistant
Staphylococcus aureus (MRSA) [43, 44]. Overall,
augmenting HIF in macrophages increases
bactericidal activity by increasing the
production of a wide range of antimicrobial
factors [43, 44]. Hypoxia leads myeloid cells to
release more nitric oxide (NO), granule
proteases, antimicrobial peptides, and
proinflammatory cytokines [41, 45]. One
notable exception is superoxide generation
via the oxidative burst, which appears to
transpire with equal efficiency in wild type
and Hif1a null macrophages [41]. It is perhaps
logical that the enzymatic pathway for
superoxide generation is not elevated during
hypoxia, given that it requires the presence of
oxygen, which is by definition in short supply.
HIF has also been recognized to promote the
production of neutrophil [46] and mast cell
[47] extracellular traps, a specialized process
whereby nuclear DNA and histones are released
at tissue foci of infection to help ensnare and
kill bacteria.
DENDRITIC CELLS AND PRIMING
THE ADAPTIVE IMMUNE RESPONSE
Some innate immune cells’ also play a crucial
role in priming the adaptive immune response
through their antigen-presenting functions.
Dcs, closely related to the macrophage, serve a
pre-eminent role as antigen-presenting cells
(APCs). As such, they provide three signals to
T cells: the antigen, presented in the context of
major histocompatibility complex (MHC)-I or
MHC-II; co-stimulatory signals through ligation
of surface molecules; and cytokines and other
soluble mediators. The combination of signals
alerts the T cells to the foreign antigen, activates
them, and modulates the strength and
polarization of the adaptive immune response.
DCs are a functionally and phenotypically
diverse group of cells. They can be derived
from the myeloid or lymphoid lineages [48].
Myeloid DCs can be classified as pre-dendritic
cells (pre-DCs), conventional dendritic cells
(cDCs), and inflammatory dendritic cells
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(iDCs); cDCs can be further divided into
migratory and lymphoid tissue-resident
dendritic cells.
Pre-DCs are cells without the classic
dendritic form and antigen-presenting
function, but with a capacity to develop into
DCs with little or no division. An inflammatory
or microbial stimulus might be required. For
example, monocytes can be considered pre-DCs
because they can give rise to inflammatory DC
upon exposure to inflammatory stimuli [49].
cDCs already have DC form and function.
Migratory DCs fit the profile of the textbook
DCs, and can be immature or mature.
Lymphoid tissue-resident cDCs collect and
present foreign and self-antigens in their home
organ; these cells play crucial roles in
maintaining tolerance to self-antigens,
harmless environmental antigens, and
commensal microorganisms. iDCs are
specialized for antigen capture and processing
and have limited ability to stimulate T cells.
Under steady-state conditions, iDCs mostly
reside at sites of contact between the host and
the environment, such as the skin and the
respiratory or gastrointestinal mucosa. These
sentinel cells continuously scan the
surroundings for the presence of pathogen-
associated molecular patterns (PAMPs) or
damage-associated molecular patterns
(DAMPs). Upon antigen uptake and activation
by proinflammatory cytokines and DAMPs or
PAMPs, iDCs undergo phenotypic and
functional changes called maturation.
Maturation prepares the DC to fulfill the
second half of their sentinel duty: to take the
antigens they had previously captured while
immature to the lymph nodes and present them
to T cells. At the molecular level, maturation
manifests as increased expression of MHC
antigens and co-stimulatory molecules (such
as CD83, CD80, CD86, and CD40), decreased
expression of phagocytic/endocytic receptors,
and a switch in the chemokine receptor
repertoire to downregulate receptors for
inflammatory chemokines (e.g., CCR1, CCR2,
CCR5, CCR6, and CXCR1) and upregulate
receptors for chemokines required for homing
to secondary lymphoid organs, namely CCR7
and CXCR4.
DENDRITIC CELLS AND HIF
Research into the role of HIF in DCs is
complicated by the fact that DCs are a rare cell
type and it is difficult to obtain adequate
numbers of primary cells for experimentation.
Consequently, much of the in vitro work on
DCs and HIF has been performed on human
peripheral blood monocytes or mouse bone
marrow cells differentiated into DCs by
treatment with granulocyte–macrophage
colony stimulating factor (GM-CSF) and IL-4
for periods of 7–11 days. Both methods produce
DCs most similar to iDCs [50], and not the
migratory cDCs that are likely to play an
important sentinel role in vivo.
Previous attempts to determine the role of
HIF in DC maturation have yielded
contradictory results. Various investigators
have produced data indicating that hypoxia
promotes DC maturation both alone [51, 52],
and in combination with LPS stimulus [53, 54],
as measured by decreased phagocytosis [55, 56],
increased migration [57, 58], and increased
expression of MHC and co-stimulatory
molecules [54, 56, 57, 59]. Others have come
to exactly the opposite conclusion, namely,
that hypoxia inhibits DC maturation [55],
migration [60, 61] (possibly by reducing
expression of MMP-9, which helps DC migrate
[62, 63]), and expression of co-stimulatory
molecules [60, 64, 65].
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When it comes to the effect of hypoxia and
HIF on the ability of APC to prime T cells, the
literature is no less mixed. Some groups have
shown that hypoxia and HIF increase the ability
of APCs to stimulate a T-cell response [53, 56,
66, 67] and lead to the expression of more
proinflammatory cytokines [53, 59, 60, 64, 65,
68, 69] that bias toward a TH1 response [66], and
type I interferons [70], which are essential for
the ability of DC to induce TH1 differentiation
[71]. Others have found the opposite [55, 72].
Still others have reported a mixed phenotype
among the DC in their in vitro model system
[60].
From the above literature survey, the jury is
still out on the role of HIF in priming the
adaptive immune response. Some of the
variation in reported results may be due to
differences in stimuli. Critically, the context
within which HIF is activated (hypoxia versus
inflammation) affects the results of HIF
activation. When HIF is activated by hypoxia,
it enhances transcription from a different set
of target genes than when it is activated by a
TLR ligand such as lipopolysaccharide (LPS)
[73]. Hypoxia and LPS stabilize HIF through
different pathways; LPS-induced HIF
stabilization requires both NF-jB and MyD88,
while hypoxia-induced HIF stabilization is
independent of NF-jB [73]. Furthermore,
when hypoxia is used as a stimulus in the
antigen presentation readouts, it affects not
only the APC but the T cells themselves,
further influencing the results of the
experiments.
HIF REGULATION IN T CELLS
Intriguingly, HIF appears to have certain
opposing effects on lymphoid cells of the
adaptive immune system when compared to
the properties it exhibits with myeloid cells of
the innate immune system. Hypoxia and HIF-1a
elevation reduces T-cell survival [74, 75] and
proliferation [75, 76]. Hypoxia also inhibits
T-cell activation by upregulating the inhibitory
isoform I.1 of HIF-1a [77]. When isoform I.1 was
deleted in T cells, the overall ability to fight
infection was improved, with reduced bacterial
load, increased resistance to sepsis, enhanced
M1 macrophage polarization, and the release of
more proinflammatory cytokines and less of the
anti-inflammatory IL-10 [78]. Other researchers
showed that loss of HIF-1a in T cells led to an
increase in IFNc secretion by both CD4? and
CD8? T cells [79].
Hypoxia and HIF play an important role in
tipping the balance between regulatory T cells
(Treg) and TH17 cells towards the Treg lineage.
Tregs and TH17 cells derive from naı¨ve CD4
? T
cells, with Tregs characterized by expression of
the transcription factor Foxp3 [80] and TH17s
characterized by the expression of RORcT [81].
Hypoxia leads to induction of Foxp3 in a HIF-
dependent manner [82] and increased numbers
of Tregs in vivo [82] and more potent Tregs
in vitro [83]. Knockout of Hif1a in CD4? T cells
leads to an increase in the numbers of TH1 and
TH17 cells [84]. Others have found that
differentiating naı¨ve CD4? T cells under
hypoxia followed by re-oxygenation increases
the number of TH17 cells [85], and that Hif1a
knockout in CD4? T cells results in increased
Tregs and fewer TH17 cells [86], possibly by
transcriptional activation of RORcT and
degradation of Foxp3 [86]. However, these
latter studies looked at the effect of HIF in the
presence of IL-6, which biases toward a TH17
response, or using the autoimmune disease
model of experimental autoimmune
encephalomyelitis, which creates the same bias
[86, 87]. In the absence of conditions that bias
toward the development of TH17, Tregs are
produced [82].
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COMPLEX EFFECTS OF HIF
IN THE IMMUNE RESPONSE
TO INFECTION
Taken together, the research suggests that HIF
positively regulates the activity of innate
immune cells but negatively regulates the
activity of T cells, with effects on APCs that
still require experimental clarification.
Kominsky et al. [88] have argued that the
differential HIF response mechanisms in
myeloid cells versus T cells has to do with the
fundamental metabolism exhibited by each cell
type. Myeloid lineage cells tend to glycolysis,
whereas lymphoid lineage cells tend to
oxidative phosphorylation [88]. HIF, which
promotes glycolysis in the absence of sufficient
oxygen for oxidative phosphorylation, would
therefore be most important for supporting
glycolysis in myeloid cells, which are best
adapted for taking advantage of increased
glycolysis. Conversely, supporting glycolysis in
lymphoid cells may be a less-effective way of
increasing their metabolic activity. DC can
belong to either lineage; the sometimes
contradictory research studies discussed above
have all been performed using experimental
models of myeloid DC. The hypoxia-induced
reduction in T-cell activity and increase in the
development of Tregs may aid in preventing an
uncontrolled immune response that provokes
autoimmunity or pathological tissue damage.
MANIPULATION OF HIF
BY PATHOGENS
Hypoxia-inducible factor induction is a general
part of the host response to infection. HIF is
induced in response to both Gram-positive and
Gram-negative bacteria [11, 41], as well as by
viruses [89, 90], protozoa [27], and fungi [27].
Given the centrality of HIF in the immune
response, it should come as no surprise that
some pathogens have developed immune
evasion strategies to counteract HIF. For
example, oncolytic reovirus can prevent
accumulation of HIF-1a in a proteasome-
dependent manner, without affecting Hif1a
transcription [91]. Moloney murine leukemia
virus is able to prevent HIF-1a protein
accumulation in infected mice without
affecting Hif1a gene transcription by reducing
the levels of the HIF-stabilizing host protein
Jab1 [92]. Chlamydia pneumoniae degrades HIF
by secreting the chlamydial protease-like
activity factor into the cytoplasm of infected
cells [93]. Pseudomonas aeruginosa expresses
alkyl quinolones that target the HIF-1a protein
for proteasomal degradation [94].
Infections by certain other viral pathogens
may increase HIF levels or activity, perhaps
exerting an anti-apoptotic effect that promotes
survival of the host cell they are infecting. The
carboxy terminus of HBx from hepatitis B virus
was shown to enhance the transactivation of
HIF-1a by enhancing its association with CREB-
BP [95]. The Kaposi’s sarcoma-associated
herpesvirus (KSHV) expresses a protein known
as latency-associated nuclear antigen (LANA),
which targets vHL for degradation via
ubiquitination, thereby increasing HIF protein
levels [96], and another part of LANA promotes
HIF nuclear accumulation [96]. Epstein–Barr
virus (EBV) oncoprotein latent membrane
protein 1 (LMP1) activates HIF-1a by
upregulating Siah1 E3 ubiquitin ligase by
enhancing its stability, which allows it to
increase the proteasomal degradation of prolyl
hydroxylases 1 and 3 that normally mark HIF-
1a for degradation [97]. As a result, LMP1
prevents formation of the vHL/HIF complex,
and HIF is not degraded.
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Other viral and parasitic organisms are able
to subvert HIF activity to their own benefit. HIF-
1a stimulates the transcription of HIV-1 genes
by associating with HIV-1 long terminal repeat
[98], and the JCV polyomavirus genes by
binding to the early promoter of the virus
[99]. Other viruses may be sensing HIF as a
marker of cellular stress to indicate when it is
appropriate to exit the cell. Murid herpesvirus 4
[100] and EBV [101] switch from lysogenic to
lytic when HIF levels are high. High levels of
HIF lead to the expression of platelet-activating
factor, which some pathogens then use to
increase translocation across the intestinal
epithelium [102]. Toxoplasma gondii survives
better when HIF is elevated [103]. Toxoplasma
induces HIF stabilization via activin-like
receptor kinase signaling [104]. Leishmania,
too, survives better when HIF is elevated, and
HIF inhibition reduces survival of the parasite
[105, 106].
HIF FOR PREVENTION
AND TREATMENT OF INFECTIOUS
DISEASE
As a master regulator of innate immunity, HIF
stands as a promising target for fine-tuning the
immune response. In most infections,
increasing HIF levels could be expected to
boost diverse myeloid cell antimicrobial
activities and promote clearance of infection.
Under certain conditions, particularly among
viral pathogens, HIF stabilization may promote
the extended survival of infected cells,
therefore care must be taken in determining
when HIF augmentation can be a beneficial
strategy.
Along with in vitro work showing that HIF
increases the bactericidal capacity of immune
cells, it has also been found that treating mice
with the HIF stabilizers mimosine [43] or AKB-
4924 [44] improves their ability to fight skin
infections. While HIF-boosting agents (prolyl
hydroxylase inhibitors) are in advance clinical
trials for anemia due to their ability to boost
erythropoietin production [107], no trials in
humans have been initiated to date in which
drugs that upregulate HIF are used to treat
acute bacterial infection. Nonetheless, such a
strategy could be effective for difficult clinical
scenarios such as opportunistic bacterial
infections in patients with weakened immune
systems or with pathogens exhibiting
multidrug resistance to conventional
antibiotics. Theoretically, HIF boosting may
also have an advantage in reducing the
likelihood of drug resistance; it would be
prohibitively difficult for bacteria to evolve
resistance to the whole arsenal of
antimicrobial factors that are increased when
HIF activity increases [3].
For those scenarios in which bacteriologic
control is easily achievable by conventional
antibiotics and in which pathology is being
driven by an overactive immune response to
bacterial components, HIF induction would
have unclear utility. In noninfectious
experimental LPS-induced sepsis, for example,
which provokes an immunopathological
cytokine storm, knocking out HIF in either
myeloid cells [108] or T cells [109] reduces the
severity of disease. This is in agreement with
clinical research showing that septic patients
exhibit reduced levels of HIF-1a mRNA with an
inverse relationship between mRNA level and
disease severity [110].
Inflammatory bowel disease, which involves
a complex interaction between epithelial barrier
function, mucosal immune response and the
normal colonic flora, has emerged as a
promising therapeutic target for HIF-1
boosting. Treatment of mice with HIF-boosting
agent AKB-4924 provided protection from
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chemical-induced colitis [111]. Treatment was
associated with a 50-fold decrease in serum
endotoxin in this model, along with reduction
in cytokines proinflammatory cytokines IL-1b,
IL-6, and TNF-a, while increasing the anti-
inflammatory cytokine IL-10; such protection
was not seen in colonic epithelial-specific HIF-1-
deficient mice, implicating epithelial HIF-1 as
the tissue target for AKB-4924-mediated
protection. Intestinal inflammation involves a
rapid accumulation of neutrophils at the
colonic mucosa. The transmigrating
neutrophils rapidly deplete oxygen in the local
microenvironment, stabilizing intestinal
epithelial HIF levels. Mice with chronic
granulomatous disease, deficient in reactive
oxygen species (ROS) generation, have
exaggerated neutrophil recruitment and colitis,
but pharmacological HIF stabilization with
AKB-4924 protected these animals from severe
colitis [112].
For viral infections, the landscape may be
more complicated. On the one hand, HIF is a
positive regulator of key immune response
effectors against viral infections, just as against
bacterial ones. On the other hand, since high
HIF levels encourage certain lysogenic viruses to
become lytic, activating HIF may potentially
influence reactivation phenotypes. Also, HIF
treatment in vivo could influence the antiviral
activity of plasmacytoid DCs (pDCs), and one
group has shown that HIF-1a is a negative
regulator of pDC development in vitro and
in vivo [113].
The work in APCs suggests that HIF elevation
could be effective not only in treating but also
in preventing disease, through examination of
adjuvant characteristics. To take advantage of
the positive role of HIF in innate immune cells
and avoid the negative effect of HIF on T cells, a
HIF-stabilizing agent would have to be effective
in the first hours of the immune response, but
be exhausted by 24–48 h after immune
stimulation when T cells begin activating. We
have recently reported [114] proof-of-concept
experiments using the HIF stabilizer AKB-4924
to strengthen the response to vaccination with
ovalbumin, a model antigen. In this work, DC
of mice treated with AKB-4924 showed
increased MHC and co-stimulatory molecule
expression and induced greater T-cell
proliferation, and higher titers of antibodies
were generated in mice provided the HIF-1
stabilizing agent. Further research must be
done to determine whether a HIF–1 boosting
drug could be developed fruitfully as a vaccine
adjuvant.
It is important to recognize that both HIF-1a
and HIF-2a are expressed in myeloid cells, and
many drugs, including iron-chelating agents
such as mimosine and desferioxamine, that
target HIF-1 would affect HIF-2 similary. A
potential exception to this rule is AKB-4924,
which appears to preferentially stabilize HIF-1a
[44]. The conclusions in this review were drawn
based mostly on work that exclusively analyzed
HIF-1a without specific analysis performed to
ascertain changes in HIF-2a level. While HIF-1
and HIF-2 have different tissue expression
patterns and play distinct roles in several
processes such as embryonic development and
iron homeostasis [115], but their roles in the
immune response to infection appear to be
very similar (our own unpublished data and
[115, 116]). One way in which HIF-1 and HIF-2
are known to have different effects on the
immune response is in regulation of the
neutrophil chemoattractant IL-8.
Overexpression of HIF-2a increases IL-8
expression in endothelial cells [117], and
siRNA knockdown of Hif2a reduces IL-8
expression [118], while HIF-1a overexpression
decreases IL-8 expression [119]. Researchers
have shown, however, that hypoxia, which
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stabilizes both HIF-1 and HIF-2, results in
reduced IL-8 expression [117], suggesting that
the HIF-1 response is more influential than
HIF-2 in IL-8 regulation and that a
pharmacological agent targeting both isoforms
would predominantly mirror the HIF-1 effect.
SUMMARY
Hypoxia-inducible factor, which exerts
transcription control over immune cell energy
generations and key effectors of the innate and
adaptive immune response, represents a
molecularly accessible and intriguing target for
immune-boosting therapeutics. HIF
stabilization in macrophages, neutrophils and
epithelial cells can increase levels of key
antibacterial factors including antimicrobial
peptides, nitric oxide and proinflammatory
cytokines. HIF-stabilizing agents also boosts
DC antigen presentation and T-cell priming
and provide barrier protective and
immunomodulatory functions in
inflammatory colitis. Yet differing effects of
HIF modulation in T lymphocytes may pose
complexities in the arena of antiviral therapy.
Further exploration of the disease spectrum for
which application of HIF modulation could
serve as an adjunctive therapy to classical anti-
infective therapeutics is warranted.
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